113 related articles for article (PubMed ID: 4370878)
21. [Symptomatologic value of the assay of EBV antibodies in carcinoma of the nasopharynx].
de Thé G
J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1983 Oct; 32(8):493-9. PubMed ID: 6319536
[No Abstract] [Full Text] [Related]
22. Seroepidemiological studies on carcinoma of the nasopharynx.
Lin TM; Yang CS; Chiou JF; Tu SM; Lin CC; Liu CH; Chen KP; Ito Y; Kawamura A; Hirayama T
Cancer Res; 1973 Nov; 33(11):2603-8. PubMed ID: 4355974
[No Abstract] [Full Text] [Related]
23. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy.
Henle W; Ho JH; Henle G; Chau JC; Kwan HC
Int J Cancer; 1977 Nov; 20(5):663-72. PubMed ID: 200569
[No Abstract] [Full Text] [Related]
24. [Detection of antitumor-antibodies in patients with tonsillar carcinoma (author's transl)].
Mang WL; Hammer C; Gruber F; Weinfurtner F; Allmeling A; Brendel W
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):11-5. PubMed ID: 7012490
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.
Henle W; Henle G; Ho HC; Burtin P; Cachin Y; Clifford P; de Schryver A; de-Thé G; Diehl V; Klein G
J Natl Cancer Inst; 1970 Jan; 44(1):225-31. PubMed ID: 11515035
[No Abstract] [Full Text] [Related]
26. [Screening of dominant epitopes of antigens related to antibodies in the sera of patients with nasopharyngeal carcinoma].
Zhang Y; Xiao XB; Zhang CQ; Li JL; Sun Y; Ye YZ; Feng KT
Ai Zheng; 2004 Sep; 23(9):999-1004. PubMed ID: 15363190
[TBL] [Abstract][Full Text] [Related]
27. [The nasopharyngeal carcinoma and Epstein-Barr virus (EBV) specific IgA (author's transl)].
Desgranges C
Pathol Biol (Paris); 1981 Dec; 29(10):587-9. PubMed ID: 6280123
[No Abstract] [Full Text] [Related]
28. [Studies on the relationship between clinical course and antibody titer to Epstein-Barr virus in nasopharyngeal carcinoma (author's transl)].
Inuyama Y; Saito S; Ozu R; Horiuchi M; Asaoka K
Nihon Jibiinkoka Gakkai Kaiho; 1975 Dec; 78(12):1237-43. PubMed ID: 176338
[No Abstract] [Full Text] [Related]
29. [Application of anticomplement immunoenzymatic method for the detection of EBNA in carcinoma cells and normal epithelial cells from nasopharynx (author's transl)].
Zeng Y; Pi GH; Zhang Q; Shen SJ; Zhao ML; Ma JL; Dong HJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1980 Dec; 2(4):220-3. PubMed ID: 6273001
[No Abstract] [Full Text] [Related]
30. [Interaction between Epstein-Barr virus (EBV) gene expression and antibodies to EBV in nasopharyngeal carcinomas].
Furukawa M; Nagayama I; Murono S; Takeshita H; Nishimura T; Yoshizaki T
Rinsho Byori; 1996 Sep; 44(9):832-7. PubMed ID: 8911067
[TBL] [Abstract][Full Text] [Related]
31. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
32. [Investigation of 2 families with clustering of nasopharyngeal carcinoma and detection of serum VCA-IgA antibody among their members].
Tang ZH
Zhonghua Yi Xue Za Zhi; 1983 Sep; 63(9):553-5. PubMed ID: 6317146
[No Abstract] [Full Text] [Related]
33. [The expression of HLA, Epstein-Barr virus nuclear antigen and the infiltration of T lymphocyte subsets in nasopharyngeal biopsy tissues].
Chen X; Cai Y; Sun N
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1994; 29(1):6-9. PubMed ID: 8031607
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
Kottaridis SD; Goula I; Kiparissiadis P
Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
[No Abstract] [Full Text] [Related]
35. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
Gunvén P; Klein G; Henle W; Henle G; Forsby N
Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
[TBL] [Abstract][Full Text] [Related]
36. Histological typing of nasopharyngeal carcinoma.
Shanmugaratnam K
IARC Sci Publ (1971); 1978; (20):3-12. PubMed ID: 215516
[TBL] [Abstract][Full Text] [Related]
37. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens-induced by the virus.
Pearson G; Dewey F; Klein G; Henle G; Henle W
J Natl Cancer Inst; 1970 Nov; 45(5):989-95. PubMed ID: 18605425
[TBL] [Abstract][Full Text] [Related]
38. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
[No Abstract] [Full Text] [Related]
39. Prospective study of Epstein-Barr virus antibody tetres and survival in patients with nasopharyngeal carcinoma.
Chan SH; de Thé G; Goh EH
Lancet; 1977 Apr; 1(8018):948-9. PubMed ID: 67401
[No Abstract] [Full Text] [Related]
40. Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study.
Pearson GR; Neel HB; Weiland LH; Mulroney SE; Taylor W; Goepfert H; Huang A; Levine P; Lanier A; Pilch B
Int J Cancer; 1984 Jun; 33(6):777-82. PubMed ID: 6329967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
